Centre Defence Enterprise for Themed Competition Webinar
Centre Defence Enterprise
for
Themed Competition Webinar
© Crown copyright 2013 Dstl
20 May 2014
The aim of CDE
Technology
Best providers
Barriers
20 May 2014
Funding research
Two routes to funding
Enduring
Themed
Themed competition
Requirements
Bounded
Specific
CDE themed competition
Innate response targets for therapy
Enduring challenge competition
Perpetual
Radical
£3M per year
Dstl is part of the Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
Enduring challenges
• protection • situational awareness • power • communications • data • lethality • mobility • human performance • lower cost of ownership • new capabilities
Online bid submission
CDE Portal
Only route
Low overhead
Dstl is part of the Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
Read available information
Start with –
Quick Start Guide
CDE Portal
Intellectual property
Dstl is part of the Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
Register now
CDE Innovation Network
Innate response targets for therapy
CDE themed competition March 25 - June 5 2014
20 May 2014
Key dates
• Competition launches today • Presentation to follow • Opportunity for Q&A • Webinar Tuesday 1 April • Deadline for applications Thursday 5 June 2014 at 17:00 hrs via Centre for Defence Enterprise Portal • Funding decisions to be made July 2014 • Notifications end July
© Crown copyright 2014 Dstl
20 May 2014
Background: biothreat agents
• Pathogenic for man or animals
• Very low infectious dose
• Infectious via the inhalational route
• Cause endemic disease around world
• Usually are zoonotic diseases
• Lethal or incapacitating
© Crown copyright 2014 Dstl
20 May 2014
© Crown copyright 2014 Dstl
20 May 2014
Defence against biothreats
• Many potential biothreat agents • How to defend against them? • Impossible to make a vaccine/therapy for every potential agent • Require generic therapy
Generic approach to therapy • By influencing the host response
• Requires an understanding of the host response to pathogen & safe ways to influence it
• Requires identification of relevant targets or pathways in the host
20 May 2014
© Crown copyright 2014 Dstl
Innate (host) response targets for therapy
• Objective of this competition is to look broadly across research and development to identify host cell targets and pathways
• Using data derived from diverse infection models
• Respondents to competition do not need to work directly with biothreat agents
• Ultimate aim is to apply the most innovative approaches to biothreat agents
20 May 2014
© Crown copyright 2014 Dstl
CDE themed competition specifics • Seeking innovative proposals for short projects (<1year); £30-
80k guide; (£500k total budget)
• Show proof-of-concept for your proposal; there is funding allocated for follow-on work for successful projects
• Competition divided into 3 challenges
• Respondents need to address 1 of the challenges, may address >1, do not have to address all 3
• Challenges described fully in the competition document
• Bids must be ethical and compliant with UK government legislation
20 May 2014
© Crown copyright 2014 Dstl
Challenge 1
© Crown copyright 2014 Dstl
20 May 2014
Identification of new cellular or host pathway targets
Identification of new cellular or host pathway targets • In host-pathogen model of your choice
– Does not need to be a biodefence pathogen – Does not need to be in vivo
• Conditioning of cells ex vivo eg to profile responses or prior to adoptive transfer
• Targeting cells in situ eg – to refocus them – to activate them – to induce them to traffic – to redirect them
© Crown copyright 2014 Dstl
20 May 2014
Identification of new cellular or host pathway targets May involve the identification of eg • immuno stimulants • modulators • transfection factors • chemokines, cytokines or the induction (or blockade) of these • cytokine/chemokine/growth factor receptors and application of these to modulate host responses
© Crown copyright 2014 Dstl
20 May 2014
Identification of new cellular or host pathway targets
• Some of these may be
exogenous and some endogenous factors
• Some endogenous natural
regulators /regulatory pathways may be exploited
• to reduce inflammation and to restore homeostasis
© Crown copyright 2014 Dstl
20 May 2014
Normal
Overactive Underactive
Possible outcomes Proposals for
– identification of new cellular targets /pathways – new applications of manipulating known cellular targets/pathways – demonstration that targets may be influenced beneficially, for
example to: • prevent cytotoxicity • prevent/reduce microbial invasion • reduce microbial load • restore normal cell function
© Crown copyright 2014 Dstl
20 May 2014
Challenge 2
Identification of new candidate therapies
© Crown copyright 2014 Dstl
20 May 2014
Identification of new candidate therapies Exploit appropriate cellular targets and pathways to identify new therapies by, for example:
• enhancing cell-mediated immunity • investigating novel combinations • identification and manipulation of significant
transcription factors • micro RNA-directed therapies or antagonists
© Crown copyright 2014 Dstl
20 May 2014
Possible outcomes • Candidate therapies should be druggable and generic • Proposals should show proof-of-concept
• Does not exclude the re-purposing or augmentation of existing
therapies
© Crown copyright 2014 Dstl
20 May 2014
Challenge 3
Identification of new platform technologies
© Crown copyright 2014 Dstl
20 May 2014
Identification of new platform technologies
For assessing therapeutic benefit • Novel technologies such as:
• non-invasive methods of in-vivo/ex-vivo analysis eg bio-imaging or tracking
• Transcriptomics including micro RNA analysis
• In-silico modelling of host responses
• Novel assays to monitor the host immune response
© Crown copyright 2014 Dstl
20 May 2014
Possible outcomes
• New technologies which may facilitate the identification and development of candidate therapies
• Proposals should demonstrate the impact of the technology on therapeutic development
© Crown copyright 2014 Dstl
20 May 2014
What we want • Highly innovative approaches that are significantly different from
existing technologies
• Generally technology readiness level (TRL) ≤ 3
• Generic approaches (not pathogen specific)
• Approaches applicable to intracellular pathogens where
appropriate
• Approaches that will lead to a feasible clinical product
© Crown copyright 2014 Dstl
20 May 2014
What we don’t want Proposals that concern: • high technology readiness level (TRL) capability • serological targets only (rather than cellular) • antibody-based therapies (but antibodies as a targeting
mechanism are acceptable) • existing solutions or technology already tested and found to
have limited utility • a paper study or review or similar • pre-exposure therapies or therapeutics • topical therapies for wounds
© Crown copyright 2014 Dstl
20 May 2014
Successful proposals
• Each will be assigned a Technical Partner
– Provides interface between project and defence community
– If project successful, potential routes to exploitation developed
© Crown copyright 2014 Dstl
20 May 2014
Summary
• Competition launches today • Webinar Tuesday 1 April • Closes on Thursday 5 June 2014 at 17:00 hrs • Short proof-of-concept proposals • If successful, potential for follow-on funding • May include additional research to develop technology for MOD • Competition information available on CDE website
www.science.mod.uk
© Crown copyright 2014 Dstl
20 May 2014
Questions?
© Crown copyright 2014 Dstl
20 May 2014
Dstl is part of the Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
w: www.science.mod.uk
@dstlmod #dstlcde
LinkedIn group – search ‘Centre for Defence Enterprise’
Keep in touch